REFERENCES 1. Disis ML, Wallace DR, Gooley TA, et al: Concurrent trastuzumab and HER2/neu- specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27:4685 -92, 2009 2. Peoples GE, G urney JM, Hueman MT, et al: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high -risk breast cancer patients. J Clin Oncol 23:7536- 45, 2005 3. Holmes JP, Clifton GT, Patil R, et al: Use of booster inoculations to sustain the cli nical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I -01 and I-02. Cancer 117:463- 71, 2011 4. Jackisch C: HER -2-positive metastatic breast cancer: optimizing trastuzumab -based therapy. Oncologist 11 Suppl 1:34- 41, 2006 5. Schaller G, Bangemann N, Becker C, et al: Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein. J Cancer Res Clin Oncol 125:520- 4, 1999 6. Kaech SM, Wherry EJ, Ahmed R: Effector and memo ry T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2:251- 62, 2002 7. Harty JT, Badovinac VP: Shaping and reshaping CD8+ T -cell memory. Nat Rev Immunol 8:107 -19, 2008 8. Disis ML, Gooley TA, Rinn K, et al: Generation of T -cell immunity to the HER -2/neu protein after active immunization with HER -2/neu peptide -based vaccines. J Clin Oncol 20:2624- 32, 2002 9. Mittendorf EA, Clifton GT, Holmes JP, et al: Clinical trial results of the HER -2/neu (E75) vaccine to prevent breast cancer recurrence in high -risk patients: from US Military Cancer Institute Clinical Trials Group Study I -01 and I -02. Cancer 118:2594- 602, 2012 10. Swain SM, Kim SB, Cortes J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2 -positive metastatic breast cance r (CLEOPATRA study): overall survival results from a randomised, double - blind, placebo -controlled, phase 3 study. Lancet Oncol 14:461- 71, 2013 11. Kambayashi T, Laufer TM: Atypical MHC class II -expressing antigen -presenting cells: can anything replace a de ndritic cell? Nat Rev Immunol 14:719 -30, 2014 12. De Koker S, Lambrecht BN, Willart MA, et al: Designing polymeric particles for antigen delivery. Chem Soc Rev 40:320- 39, 2011 13. Atanackovic D, Altorki NK, Cao Y, et al: Booster vaccination of cancer patie nts with MAGE -A3 protein reveals long -term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 105:1650- 5, 2008 14. Specht JM, Tam SL, Kurland BF, et al: Serial 2 -[18F] fluoro -2-deoxy- D-glucose positron emission tomography (FDG -PET) to monitor treatment of bone -dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 105:87- 94, 2007 15. Koo PJ, Klingensmith WC, Lewis KD, et al: Anti- CTLA4 antibody therapy related complications on FDG PET/CT. Clin Nucl Med 39:e93- 6, 2014 16. Aarntzen EH, Srinivas M, Punt CJ, et al: Insight into the dynamics, localization and magnitude of antigen -specific immune responses by [(18)F]FLT PET imaging. Oncoimmunology 1:744- 745, 2012 17. Engell -Noerregaard L, Hendel HW, Johannesen HH, et al: FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer Immunol Immunother 62:17- 25, 2013 18. Comoli P, Pedrazzoli P, Maccario R, et al: Cell therapy of stage IV n asopharyngeal carcinoma with autologous Epstein -Barr virus -targeted cytotoxic T lymphocytes. J Clin Oncol 23:8942 -9, 2005 19. Disis ML, Dang Y, Coveler AL, et al: HER -2/neu vaccine -primed autologous T -cell infusions for the treatment of advanced stage HER -2/neu expressing cancers. Cancer Immunol Immunother 63:101- 9, 2014 6304p Protocol 118 04/06/2016 16 SCHEDULE OF EVENTS Visit Time Point Procedures Booster 1 • Sign consent • Medical history and complete physical examination • Vitals signs -including weight • ECOG scoring • Pregnancy urine dip – if applicable • Clinical labs: complete blood counts, serum chemistries • Research blood: approximately 110 mls • Symptom assessment • Booster vaccine #1 • Post-immunization monitoring Forty -eight hours after booster #1 • DTH measurement of vaccine site • Research blo od: approximately 100 mls Booster 2: Six months post first booster vaccine • FDG -PET scan prior to vaccination • Complete physical examination • ECOG scoring • Pregnancy urine dip – if applicable • Vitals signs -including weight • Clinical labs: complete blood counts, serum chemistries • Research blood prior to vaccination: approximately 110 mls • Symptom/toxicity assessment • Booster vaccine #2 • Post-immunization monitoring Forty -eight hours after booster #2 • DTH evaluation • Research blood: approximately 100 mls • FDG PET Scan Six months after booster #2 • Research blood: approximately 210 mls Long -Term Follow - Up for 5 years • Every 6 months for 5 years • Medical documentation request of your oncologist • During the consent process, and at subsequent visits, patients will be instru cted to hydrate sufficiently prior to visits requiring large volume blood draws.